Combining anti-FAK and MEK therapy would be valuable in lung cancer patients presenting KRAS or BRAF mutations, as these alterations are known to activate the FAK signaling cascade on top of the classical MAPK cascade involving MEK1/2. Here, MAP2K7 is linked to lung carcinoma.